These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32026474)

  • 1. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
    Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
    Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
    Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
    Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.
    Abeykoon JP; Murray DL; Murray I; Jevremovic D; Otteson GE; Dispenzieri A; Arendt BK; Dasari S; Gertz M; Gonsalves WI; Kourelis TV; Muchtar E; Dingli D; Warsame R; Go RS; Lacy MQ; Leung N; Buadi F; Lin Y; Kyle RA; Rajkumar V; Kumar S; Kapoor P
    Br J Haematol; 2021 Apr; 193(2):380-385. PubMed ID: 33216966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
    Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
    Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
    Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
    Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
    Chapman JR; Thoren KL
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101142. PubMed ID: 32139008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
    Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
    J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
    Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
    Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
    Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
    Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma.
    Deulofeu M; Kolářová L; Salvadó V; María Peña-Méndez E; Almáši M; Štork M; Pour L; Boadas-Vaello P; Ševčíková S; Havel J; Vaňhara P
    Sci Rep; 2019 May; 9(1):7975. PubMed ID: 31138828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable disease evaluation in patients with myeloma.
    Roshal M
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
    Bai Y; Chim CS
    Hematology; 2019 Dec; 24(1):533-537. PubMed ID: 31280705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Method Aimed to Quickly Identify Pathogen and Drug Susceptibility Test Based on Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry Combined with Flow Cytometry.
    Gu YF; Li Y; Zhang XL; Yu LM; Huang BH; Sun CM
    Surg Infect (Larchmt); 2019 Apr; 20(3):219-224. PubMed ID: 30657423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bringing mass spectrometry into the care of patients with multiple myeloma.
    Murray DL
    Int J Hematol; 2022 Jun; 115(6):790-798. PubMed ID: 35471500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
    Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
    Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.